LNAI
Lunai Bioworks Inc.
Biotechnology
Market Cap$7M
5Y Perf.-33.1%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
LNAI vs BEAM vs TWST vs CDNA vs SRPT
Revenue, margins, valuation, and 5-year total return — side by side.
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.24B
5Y Perf.+23.6%
TWST
Twist Bioscience Corporation
Medical - Diagnostics & Research
Market Cap$3.48B
5Y Perf.+47.4%
CDNA
CareDx, Inc
Medical - Diagnostics & Research
Market Cap$1.11B
5Y Perf.-33.4%
SRPT
Sarepta Therapeutics, Inc.
Biotechnology
Market Cap$2.02B
5Y Perf.-87.4%
LNAI vs BEAM vs TWST vs CDNA vs SRPT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LNAI | BEAM | TWST | CDNA | SRPT |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $7M | $3.24B | $3.48B | $1.11B | $2.02B |
| Revenue (TTM) | $0.00 | $132M | $409M | $413M | $2.18B |
| Net Income (TTM) | $-126M | $-65M | $-81M | $-8M | $65M |
| Gross Margin | — | -64.2% | 52.1% | 48.2% | 34.4% |
| Operating Margin | — | -281.0% | -33.9% | -3.3% | -1.9% |
| Forward P/E | — | — | — | 22.8x | 5.7x |
| Total Debt | $10M | $294M | $137M | $20M | $1.04B |
| Cash & Equiv. | $93K | $295M | $183M | $65M | $801M |
LNAI vs BEAM vs TWST vs CDNA vs SRPT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LNAI
BEAM
TWST
CDNA
SRPT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Beam Therapeutics I… (BEAM) | 100 | 123.6 | +23.6% |
| Twist Bioscience Co… (TWST) | 100 | 147.4 | +47.4% |
| CareDx, Inc (CDNA) | 100 | 66.6 | -33.4% |
| Sarepta Therapeutic… (SRPT) | 100 | 12.6 | -87.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LNAI vs BEAM vs TWST vs CDNA vs SRPT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRPT leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. LNAI also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
LNAI
Lunai Bioworks Inc.
The Income Pick
LNAI ranks third and is worth considering specifically for income & stability.
- beta 0.71
- Beta 0.71 vs TWST's 2.41
Best for: income & stability
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs CDNA's 13.8%
- +73.1% vs LNAI's -86.6%
Best for: growth exposure
TWST
Twist Bioscience Corporation
The Long-Run Compounder
TWST is the clearest fit if your priority is long-term compounding.
- 299.6% 10Y total return vs CDNA's 405.9%
Best for: long-term compounding
CDNA
CareDx, Inc
The Defensive Pick
CDNA is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.36, Low D/E 6.5%, current ratio 2.86x
- Beta 1.36, current ratio 2.86x
Best for: sleep-well-at-night and defensive
SRPT
Sarepta Therapeutics, Inc.
The Value Play
SRPT carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (5.7x vs 22.8x)
- 3.0% margin vs BEAM's -49.2%
- 1.9% ROA vs LNAI's -18.8%, ROIC -31.4% vs -22.4%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs CDNA's 13.8% |
| Value | SRPT | Lower P/E (5.7x vs 22.8x) |
| Quality / Margins | SRPT | 3.0% margin vs BEAM's -49.2% |
| Stability / Safety | LNAI | Beta 0.71 vs TWST's 2.41 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | BEAM | +73.1% vs LNAI's -86.6% |
| Efficiency (ROA) | SRPT | 1.9% ROA vs LNAI's -18.8%, ROIC -31.4% vs -22.4% |
LNAI vs BEAM vs TWST vs CDNA vs SRPT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
LNAI vs BEAM vs TWST vs CDNA vs SRPT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSRPTLAGGINGBEAM
Who Leads Where
SRPT leads in 2 of 6 categories
CDNA leads 1 • TWST leads 1 • LNAI leads 0 • BEAM leads 0 • 1 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
LNAILunai Bioworks Inc.
0leads
CDNACareDx, Inc
1leads
TWSTTwist Bioscience Corp…
1leads
SRPTSarepta Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs TWSTvs CDNAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SRPT3/6
Valuation MetricsMultiples, price ratios, and targets
SRPT3/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CDNA5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TWST4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SRPT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRPT and LNAI operate at a comparable scale, with $2.2B and $0 in trailing revenue. SRPT is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to BEAM's -49.2%. On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | LNAILunai Bioworks In… | BEAMBeam Therapeutics… | TWSTTwist Bioscience … | CDNACareDx, Inc | SRPTSarepta Therapeut… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $132M | $409M | $413M | $2.2B |
| EBITDAEarnings before interest/tax | -$12M | -$355M | -$115M | $2M | -$6M |
| Net IncomeAfter-tax profit | -$126M | -$65M | -$81M | -$8M | $65M |
| Free Cash FlowCash after capex | -$6M | -$384M | -$95M | $65M | $107M |
| Gross MarginGross profit ÷ Revenue | — | -64.2% | +52.1% | +48.2% | +34.4% |
| Operating MarginEBIT ÷ Revenue | — | -2.8% | -33.9% | -3.3% | -1.9% |
| Net MarginNet income ÷ Revenue | — | -49.2% | -19.8% | -2.0% | +3.0% |
| FCF MarginFCF ÷ Revenue | — | -2.9% | -23.2% | +15.8% | +4.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% | +19.3% | +39.0% | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +80.8% | +26.6% | -7.6% | +126.3% | +162.6% |
SRPT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
SRPT leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | LNAILunai Bioworks In… | BEAMBeam Therapeutics… | TWSTTwist Bioscience … | CDNACareDx, Inc | SRPTSarepta Therapeut… |
|---|---|---|---|---|---|
| Market CapShares × price | $7M | $3.2B | $3.5B | $1.1B | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $17M | $3.2B | $3.4B | $1.1B | $2.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -38.99x | -43.04x | -53.50x | -2.68x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 22.81x | 5.66x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 23.22x | 9.25x | 2.91x | 0.92x |
| Price / BookPrice ÷ Book value/share | — | 2.52x | 7.08x | 3.76x | 1.76x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 30.61x | — |
SRPT leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
CDNA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SRPT delivers a 4.9% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-3 for LNAI. CDNA carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to SRPT's 0.91x. On the Piotroski fundamental quality scale (0–9), CDNA scores 5/9 vs LNAI's 1/9, reflecting solid financial health.
| Metric | LNAILunai Bioworks In… | BEAMBeam Therapeutics… | TWSTTwist Bioscience … | CDNACareDx, Inc | SRPTSarepta Therapeut… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -5.9% | -17.5% | -2.6% | +4.9% |
| ROA (TTM)Return on assets | -18.8% | -4.6% | -12.5% | -1.9% | +1.9% |
| ROICReturn on invested capital | -22.4% | -31.1% | -26.9% | -5.7% | -31.4% |
| ROCEReturn on capital employed | -33.2% | -33.3% | -24.9% | -5.8% | -24.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 4 | 5 | 4 |
| Debt / EquityFinancial leverage | — | 0.24x | 0.29x | 0.06x | 0.91x |
| Net DebtTotal debt minus cash | $10M | -$1M | -$46M | -$46M | $238M |
| Cash & Equiv.Liquid assets | $92,700 | $295M | $183M | $65M | $801M |
| Total DebtShort + long-term debt | $10M | $294M | $137M | $20M | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | -11.70x | 1.08x | — | — | -14.00x |
CDNA leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TWST leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TWST five years ago would be worth $6,143 today (with dividends reinvested), compared to $1,343 for LNAI. Over the past 12 months, BEAM leads with a +73.1% total return vs LNAI's -86.6%. The 3-year compound annual growth rate (CAGR) favors TWST at 67.3% vs LNAI's -48.8% — a key indicator of consistent wealth creation.
| Metric | LNAILunai Bioworks In… | BEAMBeam Therapeutics… | TWSTTwist Bioscience … | CDNACareDx, Inc | SRPTSarepta Therapeut… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -68.5% | +16.4% | +72.7% | +11.8% | -10.2% |
| 1-Year ReturnPast 12 months | -86.6% | +73.1% | +69.8% | +30.8% | -47.4% |
| 3-Year ReturnCumulative with dividends | -86.6% | -5.3% | +368.2% | +165.8% | -84.1% |
| 5-Year ReturnCumulative with dividends | -86.6% | -52.8% | -38.6% | -66.0% | -74.1% |
| 10-Year ReturnCumulative with dividends | -86.6% | +68.4% | +299.6% | +405.9% | +17.7% |
| CAGR (3Y)Annualised 3-year return | -48.8% | -1.8% | +67.3% | +38.5% | -45.8% |
TWST leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LNAI and CDNA each lead in 1 of 2 comparable metrics.
Risk & Volatility
LNAI is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than TWST's 2.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.1% from its 52-week high vs LNAI's 12.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LNAILunai Bioworks In… | BEAMBeam Therapeutics… | TWSTTwist Bioscience … | CDNACareDx, Inc | SRPTSarepta Therapeut… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.71x | 2.08x | 2.41x | 1.36x | 1.95x |
| 52-Week HighHighest price in past year | $2.45 | $36.44 | $66.00 | $23.24 | $44.14 |
| 52-Week LowLowest price in past year | $0.15 | $15.35 | $23.30 | $10.96 | $10.42 |
| % of 52W HighCurrent price vs 52-week peak | +12.5% | +86.7% | +84.8% | +92.1% | +43.3% |
| RSI (14)Momentum oscillator 0–100 | 44.9 | 57.7 | 50.3 | 58.8 | 41.8 |
| Avg Volume (50D)Average daily shares traded | 25.9M | 2.0M | 1.2M | 647K | 2.9M |
Evenly matched — LNAI and CDNA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BEAM as "Buy", TWST as "Buy", CDNA as "Buy", SRPT as "Buy". Consensus price targets imply 32.2% upside for SRPT (target: $25) vs 8.1% for TWST (target: $61).
| Metric | LNAILunai Bioworks In… | BEAMBeam Therapeutics… | TWSTTwist Bioscience … | CDNACareDx, Inc | SRPTSarepta Therapeut… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $40.83 | $60.50 | $24.00 | $25.29 |
| # AnalystsCovering analysts | — | 27 | 13 | 13 | 54 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.0% | +7.9% | +1.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
SRPT leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). CDNA leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallSarepta Therapeutics, Inc. (SRPT)Leads 2 of 6 categories
Loading custom metrics...
LNAI vs BEAM vs TWST vs CDNA vs SRPT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is LNAI or BEAM or TWST or CDNA or SRPT a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 13. 8% for CareDx, Inc (CDNA). Analysts rate Beam Therapeutics Inc. (BEAM) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LNAI or BEAM or TWST or CDNA or SRPT?
Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -38.
6%, compared to -86. 6% for Lunai Bioworks Inc. (LNAI). Over 10 years, the gap is even starker: CDNA returned +405. 9% versus LNAI's -86. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LNAI or BEAM or TWST or CDNA or SRPT?
By beta (market sensitivity over 5 years), Lunai Bioworks Inc.
(LNAI) is the lower-risk stock at 0. 71β versus Twist Bioscience Corporation's 2. 41β — meaning TWST is approximately 239% more volatile than LNAI relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — LNAI or BEAM or TWST or CDNA or SRPT?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus 13. 8% for CareDx, Inc (CDNA). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LNAI or BEAM or TWST or CDNA or SRPT?
Lunai Bioworks Inc.
(LNAI) is the more profitable company, earning 0. 0% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNAI leads at 0. 0% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is LNAI or BEAM or TWST or CDNA or SRPT more undervalued right now?
On forward earnings alone, Sarepta Therapeutics, Inc.
(SRPT) trades at 5. 7x forward P/E versus 22. 8x for CareDx, Inc — 17. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SRPT: 32. 2% to $25. 29.
07Which pays a better dividend — LNAI or BEAM or TWST or CDNA or SRPT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is LNAI or BEAM or TWST or CDNA or SRPT better for a retirement portfolio?
For long-horizon retirement investors, Lunai Bioworks Inc.
(LNAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNAI: -86. 6%, BEAM: +68. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between LNAI and BEAM and TWST and CDNA and SRPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LNAI is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock; TWST is a small-cap high-growth stock; CDNA is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.